Cytyc, Xoft settles brachytherapy IP row:
This article was originally published in Clinica
Cytyc, the Marlborough, Massachusetts-based specialist in women's health and cancer diagnostics, has resolved an intellectual property dispute with radiotherapy company Xoft concerning balloon-based brachytherapy technologies developed by both firms to treat breast cancer patients. The settlement will see Fremont, California-based Xoft pay Cytyc royalties of an undisclosed sum, for which the former will gain the freedom to continue selling its Axxent electronic brachytherapy system. The two companies have also agreed to discuss potential opportunities to co-develop technologies in several areas, including women's health.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.